The National Medical Products Administration (NMPA) in China has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils.

中国国家医药产品管理局（NMPA）已批准Dupixent（dupilumab）作为成人不受控制的慢性阻塞性肺疾病（COPD）的附加维持治疗，其特征是血液嗜酸性粒细胞升高。

Specifically, the approval covers patients already on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate. Dupixent for the treatment of COPD has been approved in more than 30 countries worldwide, including the 27 countries in the EU..

具体而言，该批准涵盖已经使用吸入性皮质类固醇（ICS），长效β2激动剂（LABA）和长效毒蕈碱拮抗剂（LAMA）组合的患者，或者如果ICS不合适，则使用LABA和LAMA组合的患者。用于治疗COPD的Dupixent已在全球30多个国家获得批准，其中包括欧盟27个国家。。

Professor Kang Jian; Chair of COPD Branch, Chinese Association of Chest Physicians, CMDA, Respiratory Department of First Hospital of China Medical University;“The impact of COPD extends far beyond the patient. Debilitating breathlessness and irreversible lung damage make it difficult for patients to do simple daily tasks, placing a significant burden on family members, the central caregivers in Chinese families.

康健教授；中国医科大学第一医院呼吸科中国胸科医师协会COPD分会主席；“慢性阻塞性肺疾病的影响远远超出了患者的范围。令人衰弱的呼吸困难和不可逆转的肺损伤使患者难以完成简单的日常任务，给家庭成员（中国家庭的主要照顾者）带来了沉重负担。

The approval of Dupixent for COPD in China is critical, as it fills a gap in targeted therapy for the disease and provides clinicians with a new treatment approach. This offers new hope for COPD patients who remain inadequately controlled even after triple therapy, as well as those who care for them.'.

在中国批准Dupixent治疗COPD至关重要，因为它填补了该疾病靶向治疗的空白，并为临床医生提供了一种新的治疗方法。这为即使在三联疗法后仍无法得到充分控制的COPD患者以及照顾他们的患者提供了新的希望。”。

Despite the high prevalence and burden of COPD in China, public awareness is limited. The Healthy China 2030 public health initiative includes a focus on addressing chronic respiratory diseases like COPD and aims to improve the quality of life for patients with COPD.

尽管中国COPD的患病率和负担很高，但公众意识有限。“健康中国2030公共卫生倡议”的重点是解决COPD等慢性呼吸系统疾病，旨在提高COPD患者的生活质量。

Condition: Chronic Obstructive Pulmonary Disease

病情：慢性阻塞性肺病

Type: drug

类型：药物